Active surveillance for low-risk prostate cancer—an evolving international standard of care
Menée à partir des données 2009-2014 du registre national suédois des cancers portant sur 32 518 patients atteints d'un cancer de la prostate à risque modéré, faible ou très faible de récidive, cette étude analyse l'évolution de l'utilisation d'une surveillance médicale active en fonction du risque de récidive
In 2016, active surveillance has finally become standard of care for low-risk prostate cancer in the United States. Recent articles from prospective, community-based registries have shown uptake of active surveillance skyrocketing to 40% to 50% for low-risk disease in the current decade, up from rates that historically rarely exceeded 10%.1,2 A growing body of evidence indicates that active surveillance can preserve quality of life without posing substantial short- to intermediate-term oncologic risk. Based on this evidence, a recent guideline endorsed by the American Society of Clinical Oncology (ASCO) now clearly states that surveillance is not merely an option for men with low-risk disease but rather is the preferred alternative for any clinically localized, Gleason 3 + 3 cancer.3